Clinical Trial Update: Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Chronic Heart Failure [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating candesartan's effect on brain natriuretic peptide levels in chronic heart failure subjects has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Candesartan (candesartan)

Snippet

Sponsor: Takeda | Conditions: Heart Failure | Phase 3 | Status: TERMINATED